Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-10-17

FDA Approved: COMBIVENT RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Combivent Respimat to update the product labeling. Combivent Respimat is a combination inhaler containing ipratr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Combivent Respimat (ipratropium bromide and albuterol sulfate)

Snippet

SUPPL AP for COMBIVENT RESPIMAT (IPRATROPIUM BROMIDE AND ALBUTEROL)